Literature DB >> 1324312

Remission rates and significance of prognostic factors in gestational trophoblastic tumors.

A Ayhan1, E G Yapar, O Deren, H Kişnişçi.   

Abstract

The clinical courses of 82 women with gestational trophoblastic tumors were evaluated in accordance with International Federation of Gynecologists and Obstetricians staging, traditional criteria and the modified World Health Organization prognostic scoring system. The overall remission rate was 79.3% (65/82), and the mortality rate was 20.7% (17/82). All the patients with nonmetastatic stage I disease and all with prognostic scores less than or equal to 4 attained remission, whereas patients at high risk and with stage IV disease had the lowest remission and survival rates. The results support the validity of each system. However, the World Health Organization scoring system, a combination of traditional criteria and International Federation of Gynecologists and Obstetricians staging seemed to be the most reliable for predicting treatment failures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324312

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.

Authors:  L S Dobson; P C Lorigan; R E Coleman; B W Hancock
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

2.  Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects.

Authors:  F Khan; J Everard; S Ahmed; R E Coleman; M Aitken; B W Hancock
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.